Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol sustained-release capsules for coronary plaque stability in acute coronary syndrome
ChiCTR1800019389Phase 4Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of allopurinol in acute coronary syndrome (ACS) and coronary arteriosclerosis, sponsored by Union Hospital. Primary endpoint: Change in low attenuation plaque volume measured by coronary CTA. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
allopurinol
03
Conditions
acute coronary syndrome (ACS)coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR1800019389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019389.